A cure rate can be obtained with intensive cytoreductive treatment given to a subset of patients with acute myelocytic leukemia in bone marrow remission. This report updates our experience with postremission timed sequential therapy using cytarabine and daunorubicin (Ac-D-Ac) and compares it with other brief, aggressive strategies including bone marrow transplantation. The median disease-free survival (DFS) of all patients treated in remission is 2.5 years with a >40% probability of DFS at 8 years. These results are similar to those achieved with bone marrow-ablative and other intensvie but nonablative treatment plans.
|Original language||English (US)|
|Number of pages||3|
|State||Published - Jan 1 1989|
ASJC Scopus subject areas
- Cancer Research